Program
Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol
Also written as “Symbicort Turbuhaler”, “Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)” and “Budesonide/formoterol (Symbicort® Turbuhaler®)”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Drug pageBudesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 80 open or running | phase 4since Dec 17, 2007 | Oct 6, 2006 | none ahead |
| Chenpon Pharmaceuticalits history only | 10 open or running | phase 1since Aug 31, 2026 | Aug 31, 2026 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 10 open or running | phase 1since Mar 24, 2009 | Mar 24, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 6, 2006First study: phase 3 study in AsthmaFirst studyNCT00385593 · 654 enrolled · Spain
- Sep 27, 2007Phase 3 study in AsthmaNCT00536731 · 742 enrolled · Bulgaria, Czech Republic, Hungary and more
- Dec 17, 2007Phase 4 study in AsthmaNCT00576316 · 201 enrolled · Malaysia
- Feb 4, 20092 phase 3 studies in AsthmaNCT00839800, NCT00837967
- Feb 11, 20102 phase 3 studies in Pulmonary Disease, Chronic ObstructiveNCT01070784, NCT01069289
- Jun 27, 2011Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT01397890 · 793 enrolled · China, Hong Kong, Indonesia and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01397890Pulmonary Disease, Chronic Obstructive · China, Hong Kong, Indonesia and more | 4 | Completed | Jun 2013 | 793 |
| NCT01070784Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | Oct 2011 | 328 |
| NCT01069289Pulmonary Disease, Chronic Obstructive · India, Japan, Korea, Republic of and more | 3 | Completed | Mar 2011 | 1,293 |
| NCT00837967Asthma · Japan | 3 | Completed | Jul 2009 | 25 |
| NCT00839800Asthma · Argentina, Brazil, China and more | 3 | Completed | Feb 2011 | 2,091 |
| NCT00576316Asthma · Malaysia | 4 | Completed | 201 | |
| NCT00536731Asthma · Bulgaria, Czech Republic, Hungary and more | 3 | Completed | Apr 2008 | 742 |
| NCT00385593Asthma · Spain | 3 | Terminated | 654 |
How it is read
Names in the registry
- “Symbicort Turbuhaler”, 3 entries
- “Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)”, 1 entry
- “Budesonide/formoterol (Symbicort® Turbuhaler®)”, 1 entry
- “Symbicort Turbuhaler (Budesonide/formoterol)”, 1 entry
- “Budesonide/formoterol (Symbicort Turbuhaler)”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 6 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.